MTOR and lung cancer: AKT1 overexpression and gene amplification have been shown to induce lung cancer cells to become resistant to cisplatin through mTOR signaling pathway.3 Rapamycin, also known as sirolimus, is a well‐studied mTOR inhibitor and has potent immunosuppressive and antiproliferative properties.